Life Sciences Co. Exceeds Expectations in Q3/22
Source: Dr. Andre Uddin  (11/22/22)
During the quarter, the Canadian specialty biopharma performed well and maintained a healthy balance sheet, such that it raised revenue guidance for this year, noted a Research Capital Corp. report. More >

Q4/22 Catalysts Could Boost Undervalued Biopharma Stock
Source: Dr. Yale Jen  (11/22/22)
The year's final quarter is significant for this U.S.-based firm given the trio of significant clinical achievements in its sight, noted a Laidlaw & Co. report. More >

Global Drug Co. Offers US$1.35B To Boost Hematology Assets
Source: Streetwise Reports  (11/22/22)
Imago BioSciences Inc. shares traded 104.5% higher yesterday to a new 52-week high after the company reported it entered into a definitive agreement to be acquired by Merck & Co. in an all-cash transaction for US$36.00 per share. More >

FDA Awards Breakthrough Therapy Status for AMD Drug
Source: Streetwise Reports  (11/21/22)
Iveric Bio Inc. shares traded 25% higher Friday after the company reported that the U.S. FDA has granted breakthrough therapy designation for its avacincaptad pegol for use in the treatment of geographic atrophy secondary to age-related macular degeneration. More >

Pharma Co. Won't See Bump in Sales From New COVID Drug
Source: Dr. Andre Uddin  (11/18/22)
The U.S. Food and Drug Administration Advisory Panel denied the approval of this therapeutic for patients hospitalized with severe SARS-CoV-2, yet it is still a Buy, noted a Research Capital Corp. report. More >

Biopharma Co. Hopes To Turn US$30M Into US$2B
Source: Streetwise Reports  (11/17/22)
CytomX Therapeutics Inc. shares traded 32% higher after the company reported it has formed a strategic research collaboration with Regeneron Pharmaceuticals Inc. to develop next-generation bispecific immunotherapies to treat multiple cancer tumor types. More >

Biotech Co.'s Shares Rise 38% on Ph. 1/2 Wet AMD Trial Data
Source: Streetwise Reports  (11/16/22)
4D Molecular Therapeutics Inc. shares traded 38.5% higher yesterday after the company reported interim data from its Phase 1/2 clinical trial of Intravitreal 4D-150 for use in the treatment of wet age-related macular degeneration. More >

Healthcare Co.'s New Protocol 3.5X More Efficient Addiction Treatment
Source: Streetwise Reports  (11/14/22)
This U.K. healthcare company revealed a compound that's 3.5x more effective in treating alcohol use disorder than the industry standard. Now, expansion is on the horizon. More >

UK Co. Buys NARCAN® Nasal Spray Maker
Source: Streetwise Reports  (11/14/22)
Opiant Pharmaceuticals Inc. shares traded 111% higher after the company reported it entered into a definitive agreement to be acquired by Indivior Plc. for US$20.00 per share in cash. Opiant shareholders will also receive contingent value rights that are worth up to an additional US$8.00/share if certain product sales milestones are met. More >

US Biopharma Co. Is Attractive, Derisked Investment, Analyst Says
Source: Streetwise Reports  (11/11/22)
With late-stage drug candidates and major near-term catalysts, undervalued Aldeyra Therapeutics warrants a Buy to Outperform rating and consideration by potential investors, according to various analysts. More >

Biologics Co. Doubles Revenue in Q3/22
Source: Streetwise Reports  (11/11/22)
ADMA Biologics Inc. shares traded 27.5% higher yesterday after the company reported Q3/22 financial results that included a 99% YOY revenue increase. The firm added that it is raising its FY/22 revenue estimates from US$130 million to US$145 million. More >

Pharma Co. Trades 200% Higher
Source: Streetwise Reports  (11/10/22)
Merrimack Pharmaceuticals Inc. shares traded 200% higher yesterday to a new 52-week high after the company advised that Ipsen SA reported that in a Phase 3 clinical trial, Onivyde® regimen was shown to significantly improve overall survival in previously untreated patients afflicted with metastatic pancreatic ductal adenocarcinoma. More >

Nine Stocks Expert Says Should Pique Your Interest
Source: Clive Maund  (11/9/22)
Expert Clive Maund reviews the 6-month charts of nine companies he believes are worth keeping an eye on. More >

Clean Nuclear Med Tech With Quantum Blue Sky
Source: Penny Queen  (11/9/22)
With MedTech ASP Isotopes hitting NASDAQ tomorrow, expert Penny Queen reviews the company to tell you why she believes it is worth your attention. More >

Healthcare Firm Offers US$295M for Ophthalmology Co.
Source: Streetwise Reports  (11/8/22)
Shares of Oyster Point Pharma Inc. traded 38.5% higher yesterday after the firm reported it agreed to be acquired by Viatris Inc. for US$11.00 per share along with a contingent value right for a potential additional payment of up to US$2.00 per share. More >

Pharma Co. Signs Global License Deal for Eye Drops
Source: Streetwise Reports  (11/8/22)
Shares of Ocuphire Pharma Inc. traded 20% higher after the ophthalmology-focused biopharmaceutical firm reported it executed a global license agreement with FamyGen Life Sciences Inc. to develop and commercialize its Nyxol® Eye Drops for use in treating mydriasis, presbyopia, and night vision disturbances. More >

San Diego Co. Signs US$4.2B Deal To Develop mRNA Vaccines
Source: Streetwise Reports  (11/3/22)
Arcturus Therapeutics Holdings Inc. shares traded 19% higher yesterday after the firm reported it entered a global partnership with CSL Seqirus to develop and commercialize self-amplifying mRNA vaccines worldwide. More >

Pharma Co. Earns Big Rewards from Global License Deal
Source: Streetwise Reports  (11/2/22)
Kiniksa Pharmaceuticals Ltd. shares traded 12% higher yesterday after the company reported Q3/22 financial results that included a 720% YoY increase in net revenue attributed to a combination of organic growth and increases in global licensing revenue. More >

Biopharma Co. Trades 39% Higher
Source: Streetwise Reports  (11/1/22)
Actinium Pharmaceuticals Inc. shares traded 39% higher yesterday to a new 52-week high after the firm reported topline data from its Phase 3 SIERRA study of Iomab-B in patients with active relapsed or refractory acute myeloid leukemia. During the pivotal trial, Iomab-B met its primary pre-established endpoint of durable complete remission or dCR of six months post-initial remission following a bone marrow transplant. More >

Biopharma Gains Two Cancer Cell Therapy Programs and a Target Price 10 Times Current
  (10/31/22)
This developer of cancer immunotherapies will take possession of these clinical-stage assets in a transaction with GSK and subsequently advance them toward approval, noted a ROTH Capital Partners report. More >

Biotech Co. Achieves High ORRs in Ph. 1 NSCLC Trial
Source: Streetwise Reports  (10/28/22)
Shares of Nuvalent Inc. traded 60% higher to a new 52-week intraday high after the company reported initial data from its Phase 1 ARROS-1 trial of NVL-520 demonstrating positive objective response rates in patients with ROS1-Positive non-small cell lung cancer. More >

Potential ROI With German Biopharma Co. Notable
Source: Dr. Elemer Piros  (10/27/22)
This firm, with eight treatment candidates for mental health disorders in development, boasts a catalyst-rich next two months, noted a ROTH Capital Partners report. More >

Vaccine Co. Posts Positive Ph. 1/2 IPD Trial Results
Source: Streetwise Reports  (10/25/22)
Shares of Vaxcyte Inc. traded 61% higher yesterday to a new 52-week high after the company reported positive topline results from its Phase 1/2 study of VAX-24, its novel 24-valent pneumococcal conjugate vaccine candidate being developed to prevent invasive pneumococcal disease in adults 18 to 64 years of age. More >

Expert Says Buy Pharma Co. Stock 'as Soon as Possible'
Source: Clive Maund  (10/25/22)
Algernon Pharmaceuticals has entered into a clinical trial agreement with Yale and caught expert Clive Maund's attention. In light of this, Maund reviews the company's chart to tell you when he believes you should buy its stock. More >

Biopharma Co. Shows Large Potential Return
Source: Dr. Joseph Pantginis   (10/21/22)
Palatin Technologies Inc.'s third-party clinical trial of Vyleesi in women with hypoactive sexual desire disorder was just published in the Journal of Clinical Investigation, and the biopharma offers investors significant potential return, noted an H.C. Wainwright & Co. report. More >